Zak Missak - Mitigating Supply Chain Risks in the Medical Device Industry.
•Download as PPTX, PDF•
0 likes•3 views
Zak Missak:- explained that how to manage risks during the supply of medical devices is crucial to ensure the safety and effectiveness of these critical healthcare products. Several key strategies can be employed to mitigate risks throughout the supply chain. First and foremost, establishing stringent quality control measures is essential. Thoroughly vetting suppliers and manufacturers to ensure they meet regulatory standards and have robust quality management systems is crucial Zak Missak NJ:-Maintaining clear and transparent communication channels with suppliers is another important aspect of risk management. Regular dialogue and collaboration foster a better understanding of the supply chain, enabling prompt identification and resolution of any emerging risks.
Report
Share
Report
Share
Recommended
Zak Missak – The Role of Medical Device Suppliers in Supply Chain Management.
Zak Missak, a medical device supplier play a crucial role in the complex supply chain of healthcare systems, shouldering significan responsibilities to ensure the safety and efficiency of medical device distribution. These suppliers are entrusted with the task of procuring, manufacturing, storing, and delivering medical devices to healthcare facilities, making their responsibilities paramount in maintaining the overall quality of patient care.
Zak Missak - The Role of Medical Device Suppliers in Supply Chain Management.
Zak Missak, a medical device supplier play a crucial role in the complex supply chain of healthcare systems, shouldering significant responsibilities to ensure the safety and efficiency of medical device distribution. These suppliers are entrusted with the task of procuring, manufacturing, storing, and delivering medical devices to healthcare facilities, making their responsibilities paramount in maintaining the overall quality of patient care.
Understanding Risk Management & Cyber security Principles in Medical Devices
The reality is Risk Management is one of the more complex aspects of compliance and product efficacy, as risk comes in so many forms and perceptions, and on top of it risk assessments can be interpreted differently across a sector. Often decisions must be made with not enough data to accurately quantify risks. This course teaches the principles and org mindset needed to manage RM and setup cyber security. An Excerpt from ASQ MN presentation by the author Keerthi Gunasekaran
Ashfield PV Services_Trifold v6
The document describes pharmacovigilance and drug safety services provided by Ashfield Pharmacovigilance including signal detection, literature review, medical case management, global regulatory reporting, risk management, quality assurance, and IT services to support pharmacovigilance programs. Key services include signal detection and analysis, case processing, medical review, literature searching, global regulatory reporting, risk management plan development, and audit preparation. Ashfield has experience working with pharmaceutical companies to establish compliant and effective pharmacovigilance systems and processes.
Integrated Safety and Risk Management Solutions - Addressing the Needs of Sma...
Premarketing clinical safety and PV activities, and the technology infrastructure that supports it, are typically outsourced to multiple contract research organisations (CROs) as part of their clinical trial programmes. **Disclaimer: This article was previously published. Sciformix is now a Covance company.
Blurb 4th pv 2013
The 4th Pharmacovigilance 2013 conference was held on March 12-13, 2013 in London and focused on ensuring safer drugs are brought to market through analyzing the latest developments in pharmacovigilance, drug safety, and risk management. Key topics included exploiting new technologies and methodologies, the impact of new regulations, strategies for collecting and analyzing safety data, and improving patient safety. The conference featured speakers from major pharmaceutical companies and regulatory agencies and was intended for professionals in fields related to drug safety.
Recommended
Zak Missak – The Role of Medical Device Suppliers in Supply Chain Management.
Zak Missak, a medical device supplier play a crucial role in the complex supply chain of healthcare systems, shouldering significan responsibilities to ensure the safety and efficiency of medical device distribution. These suppliers are entrusted with the task of procuring, manufacturing, storing, and delivering medical devices to healthcare facilities, making their responsibilities paramount in maintaining the overall quality of patient care.
Zak Missak - The Role of Medical Device Suppliers in Supply Chain Management.
Zak Missak, a medical device supplier play a crucial role in the complex supply chain of healthcare systems, shouldering significant responsibilities to ensure the safety and efficiency of medical device distribution. These suppliers are entrusted with the task of procuring, manufacturing, storing, and delivering medical devices to healthcare facilities, making their responsibilities paramount in maintaining the overall quality of patient care.
Understanding Risk Management & Cyber security Principles in Medical Devices
The reality is Risk Management is one of the more complex aspects of compliance and product efficacy, as risk comes in so many forms and perceptions, and on top of it risk assessments can be interpreted differently across a sector. Often decisions must be made with not enough data to accurately quantify risks. This course teaches the principles and org mindset needed to manage RM and setup cyber security. An Excerpt from ASQ MN presentation by the author Keerthi Gunasekaran
Ashfield PV Services_Trifold v6
The document describes pharmacovigilance and drug safety services provided by Ashfield Pharmacovigilance including signal detection, literature review, medical case management, global regulatory reporting, risk management, quality assurance, and IT services to support pharmacovigilance programs. Key services include signal detection and analysis, case processing, medical review, literature searching, global regulatory reporting, risk management plan development, and audit preparation. Ashfield has experience working with pharmaceutical companies to establish compliant and effective pharmacovigilance systems and processes.
Integrated Safety and Risk Management Solutions - Addressing the Needs of Sma...
Premarketing clinical safety and PV activities, and the technology infrastructure that supports it, are typically outsourced to multiple contract research organisations (CROs) as part of their clinical trial programmes. **Disclaimer: This article was previously published. Sciformix is now a Covance company.
Blurb 4th pv 2013
The 4th Pharmacovigilance 2013 conference was held on March 12-13, 2013 in London and focused on ensuring safer drugs are brought to market through analyzing the latest developments in pharmacovigilance, drug safety, and risk management. Key topics included exploiting new technologies and methodologies, the impact of new regulations, strategies for collecting and analyzing safety data, and improving patient safety. The conference featured speakers from major pharmaceutical companies and regulatory agencies and was intended for professionals in fields related to drug safety.
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
The prescription drug sales have been growing globally at a rate of 12-20%, which is lucrative by any standards, especially when top companies’ total sales are approaching 25-40 billion USD a year. Such market forces create tremendous pressure on one side on the drug sponsors to launch their product as early as possible, and on the other hand on the significantly regulators to decide on the product safety for approval with a tremendous time constraint. In such a scenario, drug regulatory authorities in US, Europe and elsewhere have renewed their mandate to fortify the “safety” regulations so that the drugs released to the market are highly safe and effective. The FDA Amendment Act, 2007 (FDAAA) have now authorized FDA to significantly increase the user fees for safety initiatives and evaluations. The FDA initiatives include its authority to ask from a drug sponsor a Risk and Evaluation Mitigation Strategy (REMS) with a detailed risk minimization action plan. FDA can now require the sponsor to develop a comprehensive safety surveillance system as well. For each new drug, FDA will now also establish an internal committee for a safe use of this drug in pediatric population. Similar approaches and authorities have also been given to European drug regulatory agencies.
This presentation will take you through the current proactive risk management approaches used or proposed by the prominent regulatory agencies for both pre- and post- market safety surveillance of new drug and new drug products. It will also discuss the challenges and collaborative efforts of both regulators and industry to work with a multidisciplinary safety management system to identify and assess the risk signals as early as possible in drug development process. Further it will discuss the reporting and evaluation of this data such that it helps pre-market approval of the safest possible product and a transparent post-market surveillance plan.
pharmacovigilance set up poster
this is just an example. any resemblance to any comapny n product is just conincidence. we have prepared it for college project as an advertisement.
Zak Missak – The Role of Medical Device Suppliers in Supply Chain Management.
Zak Missak, a medical device supplier play a crucial role in the complex supply chain of healthcare systems, shouldering significan responsibilities to ensure the safety and efficiency of medical device distribution. These suppliers are entrusted with the task of procuring, manufacturing, storing, and delivering medical devices to healthcare facilities, making their responsibilities paramount in maintaining the overall quality of patient care.
Navigating Regulatory Compliance in Medical Device Manufacturing.pptx
The regulatory framework for medical devices is multi-faceted, with regulations varying across different regions.
PPT for new assignment study material for
This document discusses recent trends and challenges in global supply chains. It outlines issues supply chain managers have faced from navigating pandemic regulations to ensuring environmental sustainability and labor standards. Key challenges covered include pandemic safety protocols, environmental regulations, labor standards, contractual disputes, data privacy and security. The document suggests strategies for supply chain managers to address these, such as proactive compliance management, supplier engagement and collaboration, contractual clarity and risk mitigation, and sustainability integration.
Post Marketing Surveillance - RSI
Safeguarding Medical Devices in India: Explore the Vital Role of Post-Market Surveillance. Learn about Materiovigilance and Stay Compliant. Read Now!
Security, Compliance Loss Prevention Part 12.pptx
The document discusses key aspects of supply chain risk management. It explains that supply chain risk management involves identifying, assessing, and mitigating risks through steps like risk identification, risk assessment, developing mitigation strategies, continuous monitoring and evaluation, collaboration and communication between partners, and investment in technology. Effective supply chain risk management is important to ensure continuity and resilience against potential disruptions.
Pharmacovigilance 2010
Pharmacovigilance Conference on Drug Safety to be held in Jan 2010 at Mumbai, Provenance Research and www.pharmacovigilance.co.in are proud media partners
Review Article: PROCESS ANALYTICAL TECHNOLOGY- Innovative pharmaceutical deve...
Process Analytical Technology in pharmaceutical production checks the quality of the raw material attributes
both physically and chemically, that too off-line, in-line or on-line. Process analytical technologies have been
applied to manufacturing processes for decades. PAT is a system for design, analysis, and control of
manufacturing processes, 1
based on continuous monitoring/rapid measurements of critical quality and
performance attributes of raw material, intermediates and products. PAT involves measurement science by
using conventional process sensors such as pressure, temperature and probes. The PAT initiative was initially
intended for traditional pharmaceutical manufacturers, but the FDA.s, PAT guidance now clearly states that it
applies to all manufacturers of human and veterinary drug products. PAT involves shift from testing the quality
to building quality into products by testing at several intermediate steps. It specifically requires that
quantifiable, causal, and predictive relationships be established among the raw materials. There by decreasing
the chances of contamination and cross contamination. It also saves a huge amount of time and money required
for sampling and analysis of the products. Overall PAT paves a way for producing a quality product thus
satisfying the customer needs and creating a good brand image for the organization. PAT that will encourage
the voluntary development and implementation of innovative pharmaceutical development, manufacturing, and
quality assurance as well as novel analyzer technologies.
Signal detection and their assessment in clinical trials
Signal detection in clinical trials is a crucial aspect of pharmacovigilance that involves identifying potential safety concerns or signals associated with the use of investigational drugs. The process of signal detection is ongoing throughout the life cycle of a drug, from early-phase trials to post-marketing surveillance. Here's an overview of signal detection and the assessment process in clinical trials
Regulatory Reporting in Pharmacovigilance: Compliance and Best Practices
Regulatory reporting in pharmacovigilance is a critical component of ensuring patient safety by promptly and accurately communicating adverse events and other safety-related information to regulatory authorities. Compliance with regulatory requirements is essential to maintain public health and trust in the pharmaceutical industry.
Risk Based Monitoring in Clinical trials_Aishwarya Janjale.pptx
Risk-Based Monitoring (RBM) in clinical trials represents a departure from traditional, one-size-fits-all monitoring approaches. This innovative strategy tailors monitoring activities to the specific risks associated with a trial, optimizing resource utilization and enhancing data quality. This article explores the key principles, benefits, and challenges of RBM, illustrating its transformative impact on the landscape of clinical trial oversight.
Key Principles:
Risk Identification and Assessment:
RBM begins with a comprehensive assessment of potential risks to data integrity, patient safety, and study endpoints. These risks are identified based on factors such as study complexity, patient population, and investigational product characteristics.
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
"Understanding MedDRA: A Comprehensive Guide to Standardized Medical Terminology" offers a detailed exploration of MedDRA (Medical Dictionary for Regulatory Activities), a globally recognized and indispensable tool in the realm of healthcare regulation. This guide delves into the intricacies of MedDRA, elucidating its purpose, structure, and practical applications.
At its core, MedDRA serves as a lingua franca for the exchange of regulatory information pertaining to medical products used by humans. With its standardized classification system, MedDRA ensures consistency and clarity in the reporting and analysis of adverse events, drug indications, and other medical product information across diverse regulatory landscapes.
The guide begins by elucidating the overarching purpose of MedDRA, emphasizing its pivotal role in standardization, adverse event reporting, safety signal detection, and regulatory compliance. By providing a common language for encoding medical data, MedDRA facilitates seamless communication among stakeholders and enables rigorous scrutiny of safety profiles and risk-benefit assessments.
An in-depth exploration of MedDRA's hierarchical structure follows, delineating its five levels: System Organ Class (SOC), High-Level Group Term (HLGT), Preferred Term (PT), Low-Level Term (LLT), and Special Term (ST). Through this hierarchical framework, MedDRA categorizes medical concepts into a systematic taxonomy, facilitating precise categorization and retrieval of relevant information.
The guide further elucidates the concept of Standardized MedDRA Queries (SMQs), predefined sets of terms tailored to expedite safety signal detection and risk assessment. These queries serve as invaluable tools in pharmacovigilance activities, aiding in the identification of potential safety concerns and the evaluation of the relationship between medical events and drugs.
A crucial aspect of MedDRA explored in this guide is the process of converting data from other medical terminologies or coding systems into MedDRA. This entails a meticulous approach involving mapping, normalization, validation, integration, and user training. By adhering to these methodical steps, organizations can ensure the accuracy and reliability of converted data, thereby enhancing regulatory compliance and patient safety.
Through comprehensive coverage of mapping methods, validation procedures, and implementation strategies, this guide equips readers with the knowledge and insights needed to navigate the complexities of MedDRA effectively. Whether you are a healthcare professional, regulatory expert, or pharmaceutical industry stakeholder, "Understanding MedDRA" serves as an invaluable resource for mastering the nuances of standardized medical terminology and harnessing its power for regulatory success.
IRJET- Chronic Kidney Disease Prediction based on Naive Bayes Technique
This document discusses using a Naive Bayes technique to predict chronic kidney disease (CKD) based on patient data. It begins by introducing data mining and its applications in healthcare to extract useful information from large datasets. It then reviews literature on using classification algorithms like Naive Bayes for disease detection. Next, it describes the limitations of existing manual CKD prediction systems. The proposed system would automate CKD prediction using a Naive Bayes classifier to help doctors diagnose the disease which affects many worldwide. The methodology involves collecting clinical data, pre-processing it, then applying the Naive Bayes technique to extract patterns and predict CKD.
Systematic review of quality standards for medical devices and practice measu...
A systematic literature search performed in databases (Medline, Cochrane Library, Scopus, Embase, CRD York), selected journals and websites identified articles describing either a general MDR structure or the development process of specific registries.
Learn More : https://pubrica.com/services/research-services/systematic-review/
Reference: https://bit.ly/3MCXLOK
Why Pubrica:
When you order our services, we promise you the following – Plagiarism free | always on Time | 24*7 customer support | Written to international Standard | Unlimited Revisions support | Medical writing Expert | Publication Support | Bio statistical experts | High-quality Subject Matter Experts.
Contact us:
Web: https://pubrica.com/
Blog: https://pubrica.com/academy/
Email: sales@pubrica.com
WhatsApp : +91 9884350006
United Kingdom: +44-1618186353
Biosimilares . Un Enfoque desde la Gestión de Riesgos #PanlarCourse
Governments should actively promote pharmacovigilance of biosimilars in Latin America through a risk management approach. A risk management plan involves activities to identify, characterize, and manage medicine-related risks, including an overview of the safety profile, pharmacovigilance plan, and risk minimization plan. Experience with biologics shows that registries are important for gathering drug information. Risk management plans should be required to approve biosimilars and a Pan American registry for biologics and biosimilars should be encouraged to optimize treatment risk-benefit profiles.
Safety and Regulatory Solutions to Address the Needs of Small and Medium Biop...
Clinical trials are typically outsourced to full-service clinical research organisations (CROs) and many SMEs select them based on a CRO's ability to recruit patients in certain geographies and therapeutic areas. **Disclaimer: This article was previously published. Sciformix is now a Covance company.
Systematic review of quality standards for medical devices and practice measu...
A systematic literature search performed in databases (Medline, Cochrane Library, Scopus, Embase, CRD York), selected journals and websites identified articles describing either a general MDR structure or the development process of specific registries.
Learn More : https://pubrica.com/services/research-services/systematic-review/
Reference: https://bit.ly/3MCXLOK
Why Pubrica:
When you order our services, we promise you the following – Plagiarism free | always on Time | 24*7 customer support | Written to international Standard | Unlimited Revisions support | Medical writing Expert | Publication Support | Bio statistical experts | High-quality Subject Matter Experts.
Contact us:
Web: https://pubrica.com/
Blog: https://pubrica.com/academy/
Email: sales@pubrica.com
WhatsApp : +91 9884350006
United Kingdom: +44-1618186353
Health apps regulation and quality control case studies and session 2 present...
The document discusses regulation and quality control of health apps. It begins with an overview of the digital health landscape and how different types of apps may be regulated to varying degrees. It then discusses challenges in managing chronic diseases and how data from apps and devices could potentially help transform care if delivered in an actionable way. The rest of the document discusses regulatory frameworks for medical software and apps, standards that may apply, and issues to consider like safety, security, usability and how to demonstrate safety for apps and systems that include software.
More Related Content
Similar to Zak Missak - Mitigating Supply Chain Risks in the Medical Device Industry.
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
The prescription drug sales have been growing globally at a rate of 12-20%, which is lucrative by any standards, especially when top companies’ total sales are approaching 25-40 billion USD a year. Such market forces create tremendous pressure on one side on the drug sponsors to launch their product as early as possible, and on the other hand on the significantly regulators to decide on the product safety for approval with a tremendous time constraint. In such a scenario, drug regulatory authorities in US, Europe and elsewhere have renewed their mandate to fortify the “safety” regulations so that the drugs released to the market are highly safe and effective. The FDA Amendment Act, 2007 (FDAAA) have now authorized FDA to significantly increase the user fees for safety initiatives and evaluations. The FDA initiatives include its authority to ask from a drug sponsor a Risk and Evaluation Mitigation Strategy (REMS) with a detailed risk minimization action plan. FDA can now require the sponsor to develop a comprehensive safety surveillance system as well. For each new drug, FDA will now also establish an internal committee for a safe use of this drug in pediatric population. Similar approaches and authorities have also been given to European drug regulatory agencies.
This presentation will take you through the current proactive risk management approaches used or proposed by the prominent regulatory agencies for both pre- and post- market safety surveillance of new drug and new drug products. It will also discuss the challenges and collaborative efforts of both regulators and industry to work with a multidisciplinary safety management system to identify and assess the risk signals as early as possible in drug development process. Further it will discuss the reporting and evaluation of this data such that it helps pre-market approval of the safest possible product and a transparent post-market surveillance plan.
pharmacovigilance set up poster
this is just an example. any resemblance to any comapny n product is just conincidence. we have prepared it for college project as an advertisement.
Zak Missak – The Role of Medical Device Suppliers in Supply Chain Management.
Zak Missak, a medical device supplier play a crucial role in the complex supply chain of healthcare systems, shouldering significan responsibilities to ensure the safety and efficiency of medical device distribution. These suppliers are entrusted with the task of procuring, manufacturing, storing, and delivering medical devices to healthcare facilities, making their responsibilities paramount in maintaining the overall quality of patient care.
Navigating Regulatory Compliance in Medical Device Manufacturing.pptx
The regulatory framework for medical devices is multi-faceted, with regulations varying across different regions.
PPT for new assignment study material for
This document discusses recent trends and challenges in global supply chains. It outlines issues supply chain managers have faced from navigating pandemic regulations to ensuring environmental sustainability and labor standards. Key challenges covered include pandemic safety protocols, environmental regulations, labor standards, contractual disputes, data privacy and security. The document suggests strategies for supply chain managers to address these, such as proactive compliance management, supplier engagement and collaboration, contractual clarity and risk mitigation, and sustainability integration.
Post Marketing Surveillance - RSI
Safeguarding Medical Devices in India: Explore the Vital Role of Post-Market Surveillance. Learn about Materiovigilance and Stay Compliant. Read Now!
Security, Compliance Loss Prevention Part 12.pptx
The document discusses key aspects of supply chain risk management. It explains that supply chain risk management involves identifying, assessing, and mitigating risks through steps like risk identification, risk assessment, developing mitigation strategies, continuous monitoring and evaluation, collaboration and communication between partners, and investment in technology. Effective supply chain risk management is important to ensure continuity and resilience against potential disruptions.
Pharmacovigilance 2010
Pharmacovigilance Conference on Drug Safety to be held in Jan 2010 at Mumbai, Provenance Research and www.pharmacovigilance.co.in are proud media partners
Review Article: PROCESS ANALYTICAL TECHNOLOGY- Innovative pharmaceutical deve...
Process Analytical Technology in pharmaceutical production checks the quality of the raw material attributes
both physically and chemically, that too off-line, in-line or on-line. Process analytical technologies have been
applied to manufacturing processes for decades. PAT is a system for design, analysis, and control of
manufacturing processes, 1
based on continuous monitoring/rapid measurements of critical quality and
performance attributes of raw material, intermediates and products. PAT involves measurement science by
using conventional process sensors such as pressure, temperature and probes. The PAT initiative was initially
intended for traditional pharmaceutical manufacturers, but the FDA.s, PAT guidance now clearly states that it
applies to all manufacturers of human and veterinary drug products. PAT involves shift from testing the quality
to building quality into products by testing at several intermediate steps. It specifically requires that
quantifiable, causal, and predictive relationships be established among the raw materials. There by decreasing
the chances of contamination and cross contamination. It also saves a huge amount of time and money required
for sampling and analysis of the products. Overall PAT paves a way for producing a quality product thus
satisfying the customer needs and creating a good brand image for the organization. PAT that will encourage
the voluntary development and implementation of innovative pharmaceutical development, manufacturing, and
quality assurance as well as novel analyzer technologies.
Signal detection and their assessment in clinical trials
Signal detection in clinical trials is a crucial aspect of pharmacovigilance that involves identifying potential safety concerns or signals associated with the use of investigational drugs. The process of signal detection is ongoing throughout the life cycle of a drug, from early-phase trials to post-marketing surveillance. Here's an overview of signal detection and the assessment process in clinical trials
Regulatory Reporting in Pharmacovigilance: Compliance and Best Practices
Regulatory reporting in pharmacovigilance is a critical component of ensuring patient safety by promptly and accurately communicating adverse events and other safety-related information to regulatory authorities. Compliance with regulatory requirements is essential to maintain public health and trust in the pharmaceutical industry.
Risk Based Monitoring in Clinical trials_Aishwarya Janjale.pptx
Risk-Based Monitoring (RBM) in clinical trials represents a departure from traditional, one-size-fits-all monitoring approaches. This innovative strategy tailors monitoring activities to the specific risks associated with a trial, optimizing resource utilization and enhancing data quality. This article explores the key principles, benefits, and challenges of RBM, illustrating its transformative impact on the landscape of clinical trial oversight.
Key Principles:
Risk Identification and Assessment:
RBM begins with a comprehensive assessment of potential risks to data integrity, patient safety, and study endpoints. These risks are identified based on factors such as study complexity, patient population, and investigational product characteristics.
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
"Understanding MedDRA: A Comprehensive Guide to Standardized Medical Terminology" offers a detailed exploration of MedDRA (Medical Dictionary for Regulatory Activities), a globally recognized and indispensable tool in the realm of healthcare regulation. This guide delves into the intricacies of MedDRA, elucidating its purpose, structure, and practical applications.
At its core, MedDRA serves as a lingua franca for the exchange of regulatory information pertaining to medical products used by humans. With its standardized classification system, MedDRA ensures consistency and clarity in the reporting and analysis of adverse events, drug indications, and other medical product information across diverse regulatory landscapes.
The guide begins by elucidating the overarching purpose of MedDRA, emphasizing its pivotal role in standardization, adverse event reporting, safety signal detection, and regulatory compliance. By providing a common language for encoding medical data, MedDRA facilitates seamless communication among stakeholders and enables rigorous scrutiny of safety profiles and risk-benefit assessments.
An in-depth exploration of MedDRA's hierarchical structure follows, delineating its five levels: System Organ Class (SOC), High-Level Group Term (HLGT), Preferred Term (PT), Low-Level Term (LLT), and Special Term (ST). Through this hierarchical framework, MedDRA categorizes medical concepts into a systematic taxonomy, facilitating precise categorization and retrieval of relevant information.
The guide further elucidates the concept of Standardized MedDRA Queries (SMQs), predefined sets of terms tailored to expedite safety signal detection and risk assessment. These queries serve as invaluable tools in pharmacovigilance activities, aiding in the identification of potential safety concerns and the evaluation of the relationship between medical events and drugs.
A crucial aspect of MedDRA explored in this guide is the process of converting data from other medical terminologies or coding systems into MedDRA. This entails a meticulous approach involving mapping, normalization, validation, integration, and user training. By adhering to these methodical steps, organizations can ensure the accuracy and reliability of converted data, thereby enhancing regulatory compliance and patient safety.
Through comprehensive coverage of mapping methods, validation procedures, and implementation strategies, this guide equips readers with the knowledge and insights needed to navigate the complexities of MedDRA effectively. Whether you are a healthcare professional, regulatory expert, or pharmaceutical industry stakeholder, "Understanding MedDRA" serves as an invaluable resource for mastering the nuances of standardized medical terminology and harnessing its power for regulatory success.
IRJET- Chronic Kidney Disease Prediction based on Naive Bayes Technique
This document discusses using a Naive Bayes technique to predict chronic kidney disease (CKD) based on patient data. It begins by introducing data mining and its applications in healthcare to extract useful information from large datasets. It then reviews literature on using classification algorithms like Naive Bayes for disease detection. Next, it describes the limitations of existing manual CKD prediction systems. The proposed system would automate CKD prediction using a Naive Bayes classifier to help doctors diagnose the disease which affects many worldwide. The methodology involves collecting clinical data, pre-processing it, then applying the Naive Bayes technique to extract patterns and predict CKD.
Systematic review of quality standards for medical devices and practice measu...
A systematic literature search performed in databases (Medline, Cochrane Library, Scopus, Embase, CRD York), selected journals and websites identified articles describing either a general MDR structure or the development process of specific registries.
Learn More : https://pubrica.com/services/research-services/systematic-review/
Reference: https://bit.ly/3MCXLOK
Why Pubrica:
When you order our services, we promise you the following – Plagiarism free | always on Time | 24*7 customer support | Written to international Standard | Unlimited Revisions support | Medical writing Expert | Publication Support | Bio statistical experts | High-quality Subject Matter Experts.
Contact us:
Web: https://pubrica.com/
Blog: https://pubrica.com/academy/
Email: sales@pubrica.com
WhatsApp : +91 9884350006
United Kingdom: +44-1618186353
Biosimilares . Un Enfoque desde la Gestión de Riesgos #PanlarCourse
Governments should actively promote pharmacovigilance of biosimilars in Latin America through a risk management approach. A risk management plan involves activities to identify, characterize, and manage medicine-related risks, including an overview of the safety profile, pharmacovigilance plan, and risk minimization plan. Experience with biologics shows that registries are important for gathering drug information. Risk management plans should be required to approve biosimilars and a Pan American registry for biologics and biosimilars should be encouraged to optimize treatment risk-benefit profiles.
Safety and Regulatory Solutions to Address the Needs of Small and Medium Biop...
Clinical trials are typically outsourced to full-service clinical research organisations (CROs) and many SMEs select them based on a CRO's ability to recruit patients in certain geographies and therapeutic areas. **Disclaimer: This article was previously published. Sciformix is now a Covance company.
Systematic review of quality standards for medical devices and practice measu...
A systematic literature search performed in databases (Medline, Cochrane Library, Scopus, Embase, CRD York), selected journals and websites identified articles describing either a general MDR structure or the development process of specific registries.
Learn More : https://pubrica.com/services/research-services/systematic-review/
Reference: https://bit.ly/3MCXLOK
Why Pubrica:
When you order our services, we promise you the following – Plagiarism free | always on Time | 24*7 customer support | Written to international Standard | Unlimited Revisions support | Medical writing Expert | Publication Support | Bio statistical experts | High-quality Subject Matter Experts.
Contact us:
Web: https://pubrica.com/
Blog: https://pubrica.com/academy/
Email: sales@pubrica.com
WhatsApp : +91 9884350006
United Kingdom: +44-1618186353
Health apps regulation and quality control case studies and session 2 present...
The document discusses regulation and quality control of health apps. It begins with an overview of the digital health landscape and how different types of apps may be regulated to varying degrees. It then discusses challenges in managing chronic diseases and how data from apps and devices could potentially help transform care if delivered in an actionable way. The rest of the document discusses regulatory frameworks for medical software and apps, standards that may apply, and issues to consider like safety, security, usability and how to demonstrate safety for apps and systems that include software.
Similar to Zak Missak - Mitigating Supply Chain Risks in the Medical Device Industry. (20)
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
Pharmacovigilance: Regulators’ Perspective on Proactive Risk Management, Chal...
Zak Missak – The Role of Medical Device Suppliers in Supply Chain Management.
Zak Missak – The Role of Medical Device Suppliers in Supply Chain Management.
Navigating Regulatory Compliance in Medical Device Manufacturing.pptx
Navigating Regulatory Compliance in Medical Device Manufacturing.pptx
2- Performance Indicators MSQH Hospital Accreditation Standards 5th Edition.pdf
2- Performance Indicators MSQH Hospital Accreditation Standards 5th Edition.pdf
Review Article: PROCESS ANALYTICAL TECHNOLOGY- Innovative pharmaceutical deve...
Review Article: PROCESS ANALYTICAL TECHNOLOGY- Innovative pharmaceutical deve...
Signal detection and their assessment in clinical trials
Signal detection and their assessment in clinical trials
Regulatory Reporting in Pharmacovigilance: Compliance and Best Practices
Regulatory Reporting in Pharmacovigilance: Compliance and Best Practices
Risk Based Monitoring in Clinical trials_Aishwarya Janjale.pptx
Risk Based Monitoring in Clinical trials_Aishwarya Janjale.pptx
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
IRJET- Chronic Kidney Disease Prediction based on Naive Bayes Technique
IRJET- Chronic Kidney Disease Prediction based on Naive Bayes Technique
Systematic review of quality standards for medical devices and practice measu...
Systematic review of quality standards for medical devices and practice measu...
Biosimilares . Un Enfoque desde la Gestión de Riesgos #PanlarCourse
Biosimilares . Un Enfoque desde la Gestión de Riesgos #PanlarCourse
Safety and Regulatory Solutions to Address the Needs of Small and Medium Biop...
Safety and Regulatory Solutions to Address the Needs of Small and Medium Biop...
Systematic review of quality standards for medical devices and practice measu...
Systematic review of quality standards for medical devices and practice measu...
Health apps regulation and quality control case studies and session 2 present...
Health apps regulation and quality control case studies and session 2 present...
Zak Missak - Mitigating Supply Chain Risks in the Medical Device Industry.
- 1. ZAK MISSAK - MITIGATING SUPPLY CHAIN RISKS IN THE MEDICAL DEVICE INDUSTRY. ZAK MISSAK
- 2. • Zak Missak:- explained that how to manage risks during the supply of medical devices is crucial to ensure the safety and effectiveness of these critical healthcare products. Several key strategies can be employed to mitigate risks throughout the supply chain. First and foremost, establishing stringent quality control measures is essential. Thoroughly vetting suppliers and manufacturers to ensure they meet regulatory standards and have robust quality management
- 3. • Zak Missak NJ:-Maintaining clear and transparent communication channels with suppliers is another important aspect of risk management. Regular dialogue and collaboration foster a better understanding of the supply chain, enabling prompt identification and resolution of any emerging risks. Adherence to regulatory requirements and compliance is paramount in managing risks during the supply of medical devices. Staying up-to-date with local and international regulations, such as ISO standards and FDA guidelines, helps ensure
- 4. • Implementing robust documentation and record-keeping systems is also crucial for risk management. Accurate and comprehensive documentation allows for traceability throughout the supply chain, making it easier to identify the source of any issues or defectsRegular monitoring and surveillance of the supply chain is essential to detect and address potential risks promptly. Utilizing advanced technologies, such as track- and-trace systems, can provide real- time visibility into the movement and condition of medical devices, enabling proactive risk management and swift response to any deviations or
- 5. • In conclusion, managing risks during the supply of medical devices requires a comprehensive approach that encompasses quality control, communication, compliance, documentation, risk assessment, monitoring, and collaboration. By implementing these strategies, healthcare organizations can ensure the safe and reliable supply of medical devices, ultimately safeguarding patient well-being and improving overall healthcare outcomes.